Rockwell Medical announces FDA approval of $2.2M fee refund Rockwell Medical announced that the FDA granted its request for a small business waiver of the Prescription Drug User Fee Act, or PDUFA, fee for its New Drug Application, or NDA, for Triferic. Rockwell's previous small business waiver request was denied by the Small Business Office of Government Contracting based upon the ruling that the company did not meet the proper size determination criteria, but Rockwell appealed the decision and won. Rockwell will receive a check for $2.2M from the Department of Treasury within a few weeks. Triferic is the company's iron-replacement drug for treating iron loss in chronic kidney disease patients receiving hemodialysis. Rockwell's NDA for Triferic was accepted for filing by the FDA on May 28. The acceptance of the NDA indicates the determination by the FDA that the application is sufficiently complete to permit a substantive review. The NDA will be subject to a standard review and will have a PDUFA action date of January 24, 2015. The PDUFA action date is the goal date for the FDA to complete its review of the NDA.The company's NDA seeks approval for the marketing and sale of Triferic as an iron replacement/maintenance therapy for the treatment of iron loss or iron deficiency in adult patients with hemodialysis-dependent stage 5 chronic kidney disease.
News For RMTI From The Last 14 Days
Check below for free stories on RMTI the last two weeks.